QR код

RESPONSE TO NEOADYAVANT CHEMOTHERAPY WITH PLATINUM-BASED DRUGS IN BREAST CANCER PATIENTS WITH BRCA1 DELETION IN TUMOR

Currently, the presence of the germinal mutation BRCA1 5382insC in breast cancer patients is one of the determining factors for prescribing platinum-based drugs. However, this type of mutation is found in no more than 10 % of patients, thus limiting the feasibility of administering platinum-based dr...

Повний опис

Збережено в:
Автори: M. M. Tsyganov, N. A. Tarabanovskaya, I. V. Deryusheva, M. K. Ibragimova, P. V. Kazantseva, A. M. Pevzner, E. M. Slonimskaya, N. V. Litviakov
Формат: Artigo
Мова:Russo
Опубліковано: Russian Academy of Sciences, Tomsk National Research Medical Center 2019-06-01
Серія:Сибирский онкологический журнал
Предмети:
breast cancer
brca1
microarray analysis
digital drop pcr
neoadjuvant chemotherapy
personalized treatment
Онлайн доступ:https://www.siboncoj.ru/jour/article/view/1103
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси